Search clinical trials for: Venetoclax

Total 579 results

University Health Network, Toronto

Recruiting

Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms

Myeloproliferative Neoplasm

Canada
AbbVie

Completed

A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

Leukemia | Cancer | T-cell Prolymphocytic Leukemia (T-PLL)

United States, Australia, Austria, Finland, France, Germany, Italy, Netherlands, United Kingdom
French Innovative Leukemia Organisation

Recruiting

Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission (LAMSA2020)

Acute Myeloid Leukemia

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Active, not recruiting

Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia (VeRitAs)

Chronic Myeloid Leukemia

Italy
Austin I Kim
AstraZeneca; Genentech, Inc.

Recruiting

Avo In R/R And Previously Untreated MCL

Mantle Cell Lymphoma | Refractory Lymphoma

United States
Prelude Therapeutics

Terminated

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Follicular Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Myeloproliferative Neoplasm | Small Lymphocytic Lymphoma | B-cell Non-Hodgkin Lymphoma

United States
AbbVie
F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer...

Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)

Chronic Lymphocytic Leukemia (CLL)

United States, Australia, Austria, Bulgaria, Germany, Italy, Spain, Israel, Brazil, Romania
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | AML
Technische Universität Dresden
AbbVie; University Hospital Heidelberg

Not yet recruiting

Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML (VINCENT)

Acute Myeloid Leukemia

Germany
Akeso

Not yet recruiting

A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

ACUTE MYELOID LEUKEMIA; AML

China
The First Affiliated Hospital of Soochow University
Northern Jiangsu Province People's Hospital; The Second People's Hospital of... and other collaborators

Recruiting

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Newly Diagnosed | Acute Monocytic Leukemia

China
Shattuck Labs, Inc.

Recruiting

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States, Canada, United Kingdom
Dana-Farber Cancer Institute
BeiGene

Recruiting

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Memorial Sloan Kettering Cancer Center
AbbVie

Active, not recruiting

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

Marginal Zone Lymphoma

United States
Roswell Park Cancer Institute
AbbVie

Completed

Enzalutamide With Venetoclax in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | PSA Progression | Metastatic Prostate Carcinoma in the Soft Tissue | Castration Levels of Testosterone | Prostate Carcinoma...

United States
Celgene
AbbVie

Active, not recruiting

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

United States, Canada, France, United Kingdom, Belgium
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Refractory Acute Leukemia

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UNIFI)

Inflammatory Bowel Diseases | Colitis, Ulcerative

United States, Australia, France, Poland, Ukraine, United Kingdom, Belgium, Germany, Israel, Bulgaria, Romania, Serbia, Japan, Canada, Netherlands, Korea, Republic of, New Zealand, Russian Federation, Austria, Hungary, Slovakia, D... and more
Daewon Pharmaceutical Co., Ltd.

Unknown

Cinical Trial to Explore the Efficacy of Statin/Choline Fenofibrate Combination Therapy vs Statin Monotherapy in Patients With Inadequately Controlled TG Despite Receiving Statin Monotherapy

Dyslipidemias

Korea, Republic of
OncoVerity, Inc.

Not yet recruiting

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

Leukemia, Myeloid, Acute
University Hospital Tuebingen

Recruiting

Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML (VenSwitch)

AML | MDS

Germany
Benjamin Tomlinson

Not yet recruiting

Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

Acute Myeloid Leukemia | Myeloid Malignancy

United States
Polaris Group

Recruiting

Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Acute Myeloid Leukemia, Adult

United States
Eli Lilly and Company
Loxo Oncology, Inc.

Active, not recruiting

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML) | Myelodysplastic Syndrome (MDS) | Myeloproliferative Neoplasms (MPNs)

United States, Spain, Korea, Republic of, France, Taiwan, Australia, Belgium, Singapore, Israel, Canada, Germany, Finland
Swiss Group for Clinical Cancer Research

Completed

Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Follicular Lymphoma

Switzerland
BioFactura Australia Pty Ltd.
Avance Clinical Pty Ltd.

Completed

Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults

Psoriasis

Australia, New Zealand
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

Leukemia, Myeloid, Acute

United States, Germany, Italy, France, Australia, Spain, United Kingdom
Paolo Ghia

Recruiting

Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL) (VALUABLE)

Chronic Lymphocytic Leukemia (CLL)

Italy
Hoffmann-La Roche

Completed

A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6

Diffuse Large B-cell Lymphoma | High-Grade B-cell Lymphoma

United States, Spain, Australia, Denmark
Aprea Therapeutics

Completed

APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Myeloid Malignancy

United States
AbbVie

Terminated

A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy

Cancer | Breast Cancer

United States, Germany, Japan, Puerto Rico
Ospedale Maggiore Di Trieste

Unknown

Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Acute Myeloid Leukemia, Adult | Hypomethylating Agents | Venetoclax

Italy
Hoffmann-La Roche

Recruiting

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Belgium, Australia, Denmark, Spain, Taiwan, France, Italy, United States, Canada, Czechia, New Zealand, Poland, Finland
M.D. Anderson Cancer Center

Withdrawn

Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
Hoffmann-La Roche

Terminated

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Lymphoma, Large B-Cell, Diffuse | Follicular Lymphoma

United States, Australia, Germany, Korea, Republic of, New Zealand
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, France, Australia, Canada, Italy, Norway, Spain, Sweden, United Kingdom
Chinese PLA General Hospital
The General Hospital of Western Theater Command; First Hospital of China Medical... and other collaborators

Recruiting

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Syros Pharmaceuticals

Recruiting

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML

Acute Myeloid Leukemia

United States, France
AbbVie

Active, not recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

Japan
Ochsner Health System
Procter and Gamble

Completed

Probiotics and Multi-Drug Resistant Urinary Tract Infection

Urinary Tract Infections | Antibiotic Resistant Infection | Recurrent UTI

United States
Kowa Research Institute, Inc.

Completed

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

Severe Hypertriglyceridemia

United States, Czechia, Belarus, Hungary, Russian Federation, Poland, Bulgaria, Georgia, Ukraine
Biodel

Completed

Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500

Type 2 Diabetes Mellitus

United States
Rajshekhar Chakraborty, MD
Genentech, Inc.

Recruiting

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

AL Amyloidosis

United States
Centre Leon Berard
NETRIS Pharma

Recruiting

Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX] (AML-NET)

Acute Myeloid Leukemia Refractory

France
PureTech

Recruiting

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

MDS | AML, Adult Recurrent

United States
Shanghai Tong Ren Hospital

Recruiting

A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia (SAV)

AML, Adult

China
Kahr Medical

Recruiting

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Myelomonocytic Leukemia

United States
Dana-Farber Cancer Institute
Stemline Therapeutics, Inc.

Recruiting

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Blastic Plasmacytoid Dendritic Cell Neoplasm

United States
Takeda

Active, not recruiting

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy (PEVENAZA)

Acute Myeloid Leukemia (AML)

United States, France, Italy, Poland, Canada
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Chronic Lymphocytic Leukemia

United States

Search clinical trials for: Venetoclax

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations